Team

A. Rachel Leheny, Ph.D.

Managing Director

In 2012, Dr. Leheny co-founded Valence Advantage Life Sciences. Prior to Valence Advantage, Dr. Leheny managed Caxton Advantage which she co-founded in 2004. more

Eric W. Roberts

Managing Director

In 2012, Mr. Roberts co-founded Valence Advantage Life Sciences. Prior to Valence Advantage, Mr. Roberts managed Caxton Advantage which he co-founded in 2004. more

RECENT VALENCE NEWS

June 2, 2020

CalciMedica Announces Robert N. Wilson Formerly of J&J as Co-Chairman of the Board of Directors and Eric Roberts as Vice Chairman

May 28, 2020

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

May 22, 2020

CalciMedica Raises $15 Million in Series C Financing Round Led by Valence Life Sciences

May 21, 2020

CalciMedica Announces That FDA Has Strong Recommended Moving to a Blinded Placebo-Controlled Trial With Auxora in Patients With Severe COVID-19 Pneumonia

May 20, 2020

Atea Pharmaceuticals Announces IND Clearance of AT-527 for COVID-19 and $215 Million Financing

January 23, 2020

Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

December 9, 2019

Merck to Acquire ArQule For $2.7 Billion

November 8, 2019

HCV Viral Kinetic Analysis Predicts Shorter Treatment duration with AT-527, a Purine Nucleotide Prodrug with Potent Pan-Genotypic Antiviral Activity in HCV-Infected Subjects Regardless of Cirrhosis Status